The estimated Net Worth of Andrew Lawrence Taylor is at least 723 千$ dollars as of 19 November 2021. Mr. Taylor owns over 2,000 units of Motus GI Inc stock worth over 4,206$ and over the last 7 years he sold MOTS stock worth over 0$. In addition, he makes 719,230$ as Chief Financial Officer at Motus GI Inc.
Andrew has made over 4 trades of the Motus GI Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of MOTS stock worth 1,020$ on 19 November 2021.
The largest trade he's ever made was buying 2,000 units of Motus GI Inc stock on 19 November 2021 worth over 1,020$. On average, Andrew trades about 600 units every 137 days since 2018. As of 19 November 2021 he still owns at least 135,682 units of Motus GI Inc stock.
You can see the complete history of Mr. Taylor stock trades at the bottom of the page.
Andrew Lawrence Taylor serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Taylor served as the CFO and President of Angel Medical Systems from 2007 until 2017 and has served on the board of directors of Angel Medical Systems, Inc. since 2017. Angel Medical Systems is a medical device company that develops and manufactures ischemia monitoring and alerting systems. While at Angel Medical Systems, Mr. Taylor supervised the operations of more than fifty (50) employees in the United States and Brazil, while also overseeing the financial planning and analysis activities, capital raise efforts, and implementation of capital and operating budgets. From 2005 to 2007, Mr. Taylor was a Practice Leader for AC Lordi Consulting, where he oversaw staff providing CFO and Controller consulting services. Prior to that, Mr. Taylor was the CFO of Safe3w, Inc. from 2001 to 2005 until its acquisition by iPass, Inc. (NASDAQ: IPAS), where he led all accounting and finance functions as well as the fundraising efforts, and negotiated the sale of the company. From 1999 to 2001, Mr. Taylor served as the Vice President of Finance and Administration of Abridge, Inc., where he developed and managed processes for budgeting, forecasting and cash management. Prior to that, Mr. Taylor was a Senior Finance Associate at Delta Air Lines (NYSE: DAL), from 1998 to 1999. Mr. Taylor is a CFA Program Level II Candidate and earned a B.A. in Political Science and Economics at McGill University and his MBA in Finance at Northeastern University.
As the Chief Financial Officer of Motus GI Inc, the total compensation of Andrew Taylor at Motus GI Inc is 719,230$. There are 3 executives at Motus GI Inc getting paid more, with Timothy Moran having the highest compensation of 1,659,360$.
Andrew Taylor is 49, he's been the Chief Financial Officer of Motus GI Inc since 2017. There are 5 older and 4 younger executives at Motus GI Inc. The oldest executive at Motus GI Holdings Inc is Samuel Nussbaum, 71, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE, FL, 33301.
Over the last 7 years, insiders at Motus GI Inc have traded over 2,638,819$ worth of Motus GI Inc stock and bought 3,952,265 units worth 13,986,863$ . The most active insiders traders include Advisors Llcperceptive Life...、Larry Noracle Partners Lp F...、David P Hochman. On average, Motus GI Inc executives and independent directors trade stock every 33 days with the average trade being worth of 4,105$. The most recent stock trade was executed by Andrew Lawrence Taylor on 19 November 2021, trading 2,000 units of MOTS stock currently worth 1,020$.
motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.
Motus GI Inc executives and other stock owners filed with the SEC include: